Faeth Therapeutics, Inc. (SNSE) Form 10-Q — Aug 4, 2026
Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics, Inc.) filed its Form 10-Q for the period ended June 30, 2026, reporting financial results following its acquisition of Faeth Therapeutics in February 2026 and its corporate name change in June 2026. The company recorded a net loss of $186.2 million for the six months ended June 30, 2026, largely driven by a $133.0 million non-cash charge for acquired in-process research and development (IPR&D) related to the acquisition.
Key figures
- Acquired in process rd expense
- 132957000
- Research and development expense
- 27137000
- General and administrative expense
- 28918000
Price after filing
Close on the filing date to close N calendar days later (from $28.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.